• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Health Group Reports Second Quarter 2023 Results

    8/9/23 6:45:00 AM ET
    $BHG
    Medical Specialities
    Health Care
    Get the next $BHG alert in real time by email
    • Q2'23 Revenue from Continuing Business of $298.0 million, up 100% year over year
    • Value-Based Consumers served of 371,000, an increase of 214% on a comparable basis from last year on strong growth in Care Delivery
    • Q2'23 Net Loss from Continuing Business of $31.7 million; Positive Adjusted EBITDA of $6.4 million in Q2'23, positive Operating Income in Care Delivery and Care Solutions segments
    • Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability†

    Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported financial results for its second quarter ended June 30, 2023.

    "Bright Health showed continued strong performance in the Second Quarter, including reporting our first quarter with positive Adjusted EBITDA. Our Care Delivery and Care Solutions operating segments both performed well, with each generating positive Operating Income in the quarter," said Mike Mikan, President and CEO of Bright Health. "Additionally, we expect the sale of our California Medicare Advantage announced at the end of the Second Quarter will bolster our Balance Sheet to continue on our path to long-term profitable growth."

    Key Metrics

     

    As of June 30,

     

    2023

     

    2022

    Consumer and Patient Metrics

     

     

     

    Value-Based Consumers served1

    371,000

     

    118,000

    1The value-based care consumers at June 30, 2022 have been recast for comparability to exclude approximately 384,000 consumers attributable to our Bright HealthCare- Commercial business that we exited beginning in 2023.

     

    Three Months Ended

     

    Six Months Ended

    ($ in thousands)

    June 30

     

    June 30

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Financial Metrics

     

     

     

     

     

     

     

    Revenue

    $

    297,982

     

     

    $

    149,340

     

     

    $

    598,532

     

    ​

    $

    330,104

     

    Net Loss from Continuing Operations

    $

    (31,692

    )

     

    $

    (74,762

    )

     

    $

    (85,610

    )

    ​

    $

    (196,340

    )

    Adjusted EBITDA (non-GAAP)

    $

    6,413

     

     

    $

    (23,277

    )

     

    $

    670

     

     

    $

    (44,758

    )

    See the table at the end of this release for additional information and a reconciliation of the non-GAAP measures used in the table above.

    Financial Outlook

    For full year 2023, Bright Health is providing the following guidance and commentary:

    Bright Health is revising its 2023 financial outlook to reflect the movement of our California Medicare Advantage business to Held for Sale accounting.

    • Bright Health's Enterprise Revenue is expected to be between $1.15 billion and $1.2 billion
    • On a segment basis, Care Solutions Revenue is expected to be between $900 million and $925 million, while Care Delivery Revenue is expected to be between $250 million and $275 million
    • Enterprise Adjusted Operating Cost Ratio is expected to be between 17.5% and 18.5%†
    • Bright Health expects to be Adjusted EBITDA profitable in 2023†

    † Reconciliations of projected Adjusted EBITDA and projected Adjusted Operating Cost Ratio to the most directly comparable GAAP financial measures are not provided because the Company is unable to provide such reconciliations without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact and the periods in which the non-GAAP adjustments may be recognized. With respect to Adjusted EBITDA, these GAAP measures may include the impact of such items as interest expense, income tax expense, transaction costs, depreciation and amortization, share-based compensation expense, impairment of goodwill or intangible assets, restructuring costs, contract termination costs, changes in the fair value of contingent consideration, changes in the fair value of equity securities; and the tax effect of all such items. Historically, the Company has excluded these items from non-GAAP financial measures. With respect to Adjusted Operating Cost Ratio, these GAAP measures may include the impact of such items as share-based compensation and the impact of investment income. The Company currently expects to continue to exclude these items in future disclosures of non-GAAP financial measures and may also exclude other items that may arise (collectively, "non-GAAP adjustments"). The decisions and events that typically lead to the recognition of non-GAAP adjustments, such as a decision to exit part of the business, are inherently unpredictable as to if or when they may occur. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

    Earnings Conference Call

    As previously announced, Bright Health Group will discuss the Company's results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today. Bright Health Group will host a live webcast of this conference call which can be accessed from the Investor Relations page of the company's website (investors.brighthealthgroup.com). Following the call, a webcast replay will be available on the same site. This earnings release and the Form 8-K filed August 9, 2023 can be accessed on the Investor Relations page of the Company's website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission ("SEC") filings and public conference calls and webcasts.

    About Bright Health Group

    Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.

    Forward-Looking Statements

    Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "expect," "plan," "believe," "intend," "project," "forecast," "estimates," "projections," "outlook," "ensure," and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations with respect to Bright Health Group, Inc. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; our ability to comply with the terms of our credit facilities, including financial covenants, both during and after any applicable waiver period, and/or obtain any additional waivers of any terms of our credit facilities to the extent required; our ability to sell our Medicare Advantage business in California on acceptable terms, including our ability to receive the proceeds thereof in a manner that would alleviate our current financial position; the failure to satisfy or obtain any waiver, if applicable, of any closing condition in our agreement to sell our Medicare Advantage business in California to Molina (the "Purchase Agreement"); our ability to comply with the terms of the Purchase Agreement; whether our new credit facility will satisfy our working capital needs pending the closing of our sale of our Medicare Advantage business in California; our ability to obtain any additional short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently wind down our IFP businesses and MA businesses outside of California, including by satisfying liabilities of those businesses when due and payable; ; potential disruptions to our business due to our corporate restructuring and resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our businesses offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and add new consumers; our and our Care Partner's abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to accurately estimate our medical expenses, effectively manage our costs and claims liabilities or appropriately price our products and charge premiums; our ability to obtain claims information timely and accurately; the impact of the ongoing COVID-19 pandemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage the growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to the new risks associated with our expansion into ACO REACH; and the other factors set forth under the heading "Risk Factors" in the Company's reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.

    Bright Health Group, Inc. and Subsidiaries

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

    (Unaudited)

     

     

    June 30,

    2023

     

    December 31,

    2022

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    107,660

     

     

    $

    217,006

     

    Short-term investments

    $

    156

     

     

     

    869

     

    Accounts receivable, net of allowance of $7,653 and $6,098, respectively

    $

    27,633

     

     

     

    19,576

     

    ACO REACH performance year receivable

    $

    623,609

     

     

     

    99,181

     

    Current assets of discontinued operations (Note 14)

    $

    3,030,870

     

     

     

    3,187,464

     

    Prepaids and other current assets

     

    61,198

     

     

     

    46,538

     

    Total current assets

     

    3,851,126

     

     

     

    3,570,634

     

    Other assets:

    ​

     

     

    Long-term investments

    $

    344

     

     

     

    5,401

     

    Property, equipment and capitalized software, net

    $

    18,474

     

     

     

    21,298

     

    Goodwill

    $

    401,385

     

     

     

    401,385

     

    Intangible assets, net

    $

    99,084

     

     

     

    104,952

     

    Long-term assets of discontinued operations (Note 14)

    $

    —

     

     

     

    529,117

     

    Other non-current assets

     

    22,740

     

     

     

    32,265

     

    Total other assets

     

    542,027

     

     

     

    1,094,418

     

    Total assets

    $

    4,393,153

     

     

    $

    4,665,052

     

    Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders' Equity (Deficit)

     

     

    ​

    Current liabilities:

     

     

    ​

    Medical costs payable

    $

    179,855

     

     

    $

    116,021

     

    Accounts payable

    $

    18,476

     

     

     

    18,714

     

    ACO REACH performance year obligation

    $

    474,700

     

     

     

    —

     

    Short-term borrowings

    $

    303,947

     

     

     

    303,947

     

    Current liabilities of discontinued operations (Note 14)

    $

    2,584,890

     

     

     

    3,157,236

     

    Other current liabilities

     

    73,221

     

     

     

    97,241

     

    Total current liabilities

     

    3,635,089

     

     

     

    3,693,159

     

    Other liabilities

     

    28,792

     

     

     

    32,208

     

    Total liabilities

     

    3,663,881

     

     

     

    3,725,367

     

    Commitments and contingencies (Note 9)

    ​

     

    ​

    Redeemable noncontrolling interests

    $

    244,561

     

     

     

    219,758

     

    Redeemable Series A preferred stock, $0.0001 par value;750,000 shares authorized in 2023 and 2022; 750,000 shares issued and outstanding in 2023 and 2022

    $

    747,481

     

     

     

    747,481

     

    Redeemable Series B preferred stock, $0.0001 par value; 175,000 shares authorized in 2023 and 2022; 175,000 shares issued and outstanding in 2023 and 2022

    $

    172,936

     

     

     

    172,936

     

    Shareholders' equity (deficit):

     

     

     

    Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2023 and 2022; 7,972,033 and 7,878,394 shares issued and outstanding in 2023 and 2022*, respectively

    $

    1

     

     

     

    1

     

    Additional paid-in capital

    $

    3,021,430

     

     

     

    2,972,333

     

    Accumulated deficit

    $

    (3,444,238

    )

     

     

    (3,156,395

    )

    Accumulated other comprehensive loss

    $

    (899

    )

     

     

    (4,429

    )

    Treasury Stock, at cost, 31,526 shares at June 30, 2023, and December 31, 2022*, respectively

     

    (12,000

    )

     

     

    (12,000

    )

    Total shareholders' equity (deficit)

     

    (435,706

    )

     

     

    (200,490

    )

    Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders' equity (deficit)

    $

    4,393,153

     

     

    $

    4,665,052

     

    *Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split

    Bright Health Group, Inc. and Subsidiaries

    Consolidated Statements of Income (Loss)

    (in thousands, except share and per share data)

    (Unaudited)

     

    ​

    Three Months Ended June 30,

     

    Six Months Ended June 30,

    ​

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenue:

    ​

     

    ​

     

     

     

     

    Capitated revenue

    $

    49,764

     

     

    $

    17,641

     

     

    $

    99,312

     

     

    $

    46,289

     

    ACO REACH revenue

     

    236,994

     

     

     

    137,205

     

     

     

    476,801

     

     

     

    320,002

     

    Service revenue

     

    11,222

     

     

     

    10,732

     

     

     

    22,409

     

     

     

    20,962

     

    Investment income (loss)

     

    2

     

     

     

    (16,238

    )

     

     

    10

     

     

     

    (57,149

    )

    Total revenue

     

    297,982

     

     

     

    149,340

     

     

     

    598,532

     

     

     

    330,104

     

    Operating expenses:

     

     

    ​

     

    ​

     

    ​

    Medical costs

     

    245,160

     

     

     

    130,793

     

     

     

    505,280

     

     

     

    310,249

     

    Operating costs

     

    70,280

     

     

     

    78,997

     

     

     

    149,798

     

     

     

    175,785

     

    Restructuring charges

     

    1,285

     

     

     

    2,793

     

     

     

    1,586

     

     

     

    9,657

     

    Depreciation and amortization

     

    4,671

     

     

     

    8,276

     

     

     

    10,154

     

     

     

    16,336

     

    Total operating expenses

     

    321,396

     

     

     

    220,859

     

     

     

    666,818

     

     

     

    512,027

     

    Operating loss

     

    (23,414

    )

     

     

    (71,519

    )

     

     

    (68,286

    )

     

     

    (181,923

    )

    Interest expense

     

    9,170

     

     

     

    337

     

     

     

    16,957

     

     

     

    1,530

     

    Other income

     

    —

     

     

     

    2

     

     

     

    —

     

     

     

    2

     

    Loss from continuing operations before income taxes

     

    (32,584

    )

     

     

    (71,858

    )

     

     

    (85,243

    )

     

     

    (183,455

    )

    Income tax expense

     

    (892

    )

     

     

    2,904

     

     

     

    367

     

     

     

    12,885

     

    Net loss from continuing operations

     

    (31,692

    )

     

     

    (74,762

    )

     

     

    (85,610

    )

     

     

    (196,340

    )

    Loss from discontinued operations, net of tax (Note 14)

     

    (56,935

    )

     

     

    (176,568

    )

     

     

    (172,478

    )

     

     

    (235,619

    )

    Net Loss

     

    (88,627

    )

     

     

    (251,330

    )

     

     

    (258,088

    )

     

     

    (431,959

    )

    Net earnings from continuing operations attributable to noncontrolling interests

     

    (24,205

    )

     

     

    (23,336

    )

     

     

    (29,755

    )

     

     

    (37,941

    )

    Series A preferred stock dividend accrued

     

    (9,942

    )

     

     

    (9,461

    )

     

     

    (19,656

    )

     

     

    (18,399

    )

    Series B preferred stock dividend accrued

     

    (2,231

    )

     

     

    —

     

     

     

    (4,411

    )

     

     

    —

     

    Net loss attributable to Bright Health Group, Inc. common shareholders

    $

    (125,005

    )

     

    $

    (284,127

    )

     

    $

    (311,910

    )

     

    $

    (488,299

    )

     

     

     

     

     

     

     

     

    Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders

     

     

     

     

     

     

     

    Continuing operations

    $

    (8.55

    )

     

    $

    (13.68

    )

     

    $

    (17.59

    )

     

    $

    (32.14

    )

    Discontinued operations

     

    (7.15

    )

     

     

    (22.45

    )

     

     

    (21.76

    )

     

     

    (29.97

    )

    Basic and diluted loss per share

     

    (15.70

    )

     

     

    (36.13

    )

     

     

    (39.35

    )

     

     

    (62.11

    )

     

     

     

     

     

     

     

     

    Basic and diluted weighted-average common shares outstanding*

     

    7,962

     

     

     

    7,865

     

     

     

    7,928

     

     

     

    7,862

     

    *Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split

    Bright Health Group, Inc. and Subsidiaries

    Consolidated Statements of Cash Flows

    (in thousands)

    (Unaudited)

    ​

    Six Months Ended June 30,

    ​

     

    2023

     

     

     

    2022

     

    Cash flows from operating activities:

    ​

    ​

    ​

    Net loss

    $

    (258,088

    )

     

    $

    (431,959

    )

    Adjustments to reconcile net loss to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    16,026

     

     

     

    26,270

     

    Impairment of intangible assets

     

    —

     

     

     

    6,720

     

    Share-based compensation

     

    49,095

     

     

     

    53,141

     

    Deferred income taxes

     

    873

     

     

     

    1,154

     

    Unrealized loss on equity securities

     

    —

     

     

     

    57,151

     

    Amortization of investments

     

    (14,173

    )

     

     

    2,748

     

    Other, net

     

    3,891

     

     

     

    1,834

     

    Changes in assets and liabilities, net of acquired assets and liabilities:

     

     

     

    Accounts receivable

     

    6,284

     

     

     

    (31,404

    )

    ACO REACH performance year receivable

     

    (524,428

    )

     

     

    (396,104

    )

    Other assets

     

    57,846

     

     

     

    (60,991

    )

    Medical cost payable

     

    (567,932

    )

     

     

    231,899

     

    Risk adjustment payable

     

    10,925

     

     

     

    916,713

     

    Accounts payable and other liabilities

     

    (111,174

    )

     

     

    35,312

     

    Unearned revenue

     

    132,129

     

     

     

    3,577

     

    ACO REACH performance year obligation

     

    474,700

     

     

     

    310,603

     

    Net cash (used in) provided by operating activities

     

    (724,026

    )

     

     

    726,664

     

    Cash flows from investing activities:

     

     

     

    Purchases of investments

     

    (828,546

    )

     

     

    (1,140,896

    )

    Proceeds from sales, paydown, and maturities of investments

     

    988,749

     

     

     

    204,775

     

    Purchases of property and equipment

     

    (2,394

    )

     

     

    (15,154

    )

    Business divestitures, net of cash disposed of

     

    (682

    )

     

     

    —

     

    Business acquisitions, net of cash acquired

     

    —

     

     

     

    (310

    )

    Net cash provided by (used in) investing activities

     

    157,127

     

     

     

    (951,585

    )

    Cash flows from financing activities:

     

    ​

     

    Repayments of short-term borrowings

     

    —

     

     

     

    (155,000

    )

    Proceeds from issuance of preferred stock

     

    —

     

     

     

    747,481

     

    Proceeds from issuance of common stock

     

    2

     

     

     

    672

     

    Distributions to noncontrolling interest holders

     

    (4,952

    )

     

     

    (1,894

    )

    Net cash (used in) provided by financing activities

     

    (4,950

    )

     

     

    591,259

     

    Net increase (decrease) in cash and cash equivalents

     

    (571,849

    )

     

     

    366,338

     

    Cash and cash equivalents – beginning of year

     

    1,932,290

     

     

     

    1,061,179

     

    Cash and cash equivalents – end of period

    $

    1,360,441

     

     

    $

    1,427,517

     

    Supplemental disclosures of cash flow information:

     

     

     

    Changes in unrealized loss on available-for-sale securities in OCI

    $

    3,530

     

     

    $

    (47,051

    )

    Cash paid for interest

     

    7,700

     

     

     

    1,168

     

    Bright Health Group, Inc. and Subsidiaries

    Segment Information

    (in thousands)

    (Unaudited)

    Care Delivery

     

     

     

     

     

     

     

    ($ in thousands)

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

    Statement of income (loss) and operating data:

     

    2023

     

     

    2022

     

     

     

    2023

     

     

    2022

     

     

     

     

     

     

     

     

     

    Revenue:

     

     

     

     

     

     

     

    Capitated revenue

    $

    49,764

     

    $

    17,641

     

     

    $

    99,312

     

    $

    46,289

     

    Service revenue

     

    10,530

     

     

    10,691

     

     

     

    21,466

     

     

    20,910

     

    Total unaffiliated revenue

     

    60,294

     

     

    28,332

     

     

     

    120,778

     

     

    67,199

     

    Affiliated revenue

     

    5,774

     

     

    204,271

     

     

     

    7,969

     

     

    572,391

     

    Total segment revenue

     

    66,068

     

     

    232,603

     

     

     

    128,747

     

     

    639,590

     

    Operating expenses

     

     

     

     

     

     

     

    Medical Costs

     

    19,720

     

     

    194,531

     

     

     

    43,442

     

     

    585,998

     

    Operating Costs

     

    32,139

     

     

    32,401

     

     

     

    61,328

     

     

    63,596

     

    Depreciation and amortization

     

    3,178

     

     

    6,369

     

     

     

    6,310

     

     

    12,745

     

    Total operating expenses

     

    55,037

     

     

    233,301

     

     

     

    111,080

     

     

    662,339

     

    Operating Income (Loss)

    $

    11,031

     

    $

    (698

    )

     

    $

    17,667

     

    $

    (22,749

    )

    Care Solutions

     

     

     

     

     

     

     

    ($ in thousands)

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

    Statement of income (loss) and operating data:

     

    2023

     

     

    2022

     

     

    2023

     

     

    2022

     

     

     

     

     

     

     

     

    Revenue:

     

     

     

     

     

     

     

    ACO REACH Revenue

     

    236,994

     

     

    137,205

     

     

    476,801

     

     

    320,002

    Service revenue

     

    692

     

     

    41

     

     

    943

     

     

    52

    Total segment revenue

     

    237,686

     

     

    137,246

     

     

    477,744

     

     

    320,054

    Operating expenses

     

     

     

     

     

     

     

    Medical Costs

     

    231,279

     

     

    134,274

     

     

    469,874

     

     

    310,908

    Operating Costs

     

    3,411

     

     

    2,147

     

     

    6,383

     

     

    4,157

    Total operating expenses

     

    234,690

     

     

    136,421

     

     

    476,257

     

     

    315,065

    Operating Income

    $

    2,996

     

    $

    825

     

    $

    1,487

     

    $

    4,989

    Bright Health Group, Inc. and Subsidiaries

    Historical Financials

    Recast Income Statement(1)

    (in thousands)

    ($ in thousands)

     

     

     

     

     

    Three Months Ended

     

     

    Year Ended

    Consolidated Statements of Income (loss) and operating data:

    March 31,

     

    June 30,

     

    September 30,

     

    December 31,

     

     

    December 31,

     

    2022

     

     

     

    2022

     

     

     

    2022

     

     

     

    2022

     

     

     

     

    2022

     

    Revenue:

     

     

     

     

     

     

     

     

     

     

    Capitated revenue

    $

    28,648

     

     

    $

    17,641

     

     

    $

    33,006

     

     

    $

    33,609

     

     

     

    $

    112,904

     

    ACO REACH revenue

     

    182,797

     

     

     

    137,205

     

     

     

    145,433

     

     

     

    188,652

     

     

     

     

    654,087

     

    Service revenue

     

    10,230

     

     

     

    10,732

     

     

     

    10,076

     

     

     

    8,563

     

     

     

     

    39,601

     

    Investment income (loss)

     

    (40,911

    )

     

     

    (16,238

    )

     

     

    4,848

     

     

     

    (3,128

    )

     

     

     

    (55,429

    )

    Total revenue

     

    180,764

     

     

     

    149,340

     

     

     

    193,363

     

     

     

    227,696

     

     

     

     

    751,163

     

    Operating costs

     

     

     

     

     

     

     

     

     

     

    Medical costs

     

    179,456

     

     

     

    130,793

     

     

     

    152,150

     

     

     

    200,573

     

     

     

     

    662,972

     

    Operating costs

     

    96,788

     

     

     

    78,997

     

     

     

    85,577

     

     

     

    93,044

     

     

     

     

    354,406

     

    Restructuring charges

     

    6,864

     

     

     

    2,793

     

     

     

    5

     

     

     

    19,559

     

     

     

     

    29,221

     

    Intangibles impairment

     

    —

     

     

     

    —

     

     

     

    42,611

     

     

     

    —

     

     

     

     

    42,611

     

    Depreciation and amortization

     

    8,060

     

     

     

    8,276

     

     

     

    8,947

     

     

     

    5,427

     

     

     

     

    30,710

     

    Total operating costs

     

    291,168

     

     

     

    220,859

     

     

     

    289,290

     

     

     

    318,603

     

     

     

     

    1,119,920

     

    Operating Income (Loss)

     

    (110,404

    )

     

     

    (71,519

    )

     

     

    (95,927

    )

     

     

    (90,907

    )

     

     

     

    (368,757

    )

    Interest expense

     

    1,193

     

     

     

    337

     

     

     

    4,905

     

     

     

    6,387

     

     

     

     

    12,822

     

    Other income

     

    —

     

     

     

    2

     

     

     

    (2

    )

     

     

    —

     

     

     

     

    —

     

    Loss from continuing operations before income taxes

     

    (111,597

    )

     

     

    (71,858

    )

     

     

    (100,830

    )

     

     

    (97,294

    )

     

     

     

    (381,579

    )

    Income tax expense (benefit)

     

    9,981

     

     

     

    2,904

     

     

     

    3,401

     

     

     

    (12,622

    )

     

     

     

    3,664

     

    Net loss from continuing operations

     

    (121,578

    )

     

     

    (74,762

    )

     

     

    (104,231

    )

     

     

    (84,672

    )

     

     

     

    (385,243

    )

    Loss from discontinued operations, net of tax (Note 2)

     

    (59,051

    )

     

     

    (176,568

    )

     

     

    (155,129

    )

     

     

    (583,890

    )

     

     

     

    (974,638

    )

    Net loss

     

    (180,629

    )

     

     

    (251,330

    )

     

     

    (259,360

    )

     

     

    (668,562

    )

     

     

     

    (1,359,881

    )

    Net earnings from continuing operations attributable to noncontrolling interests

     

    (14,605

    )

     

     

    (23,336

    )

     

     

    (46,711

    )

     

     

    (11,012

    )

     

     

     

    (95,664

    )

    Series A preferred stock dividend accrued

     

    (8,938

    )

     

     

    (9,461

    )

     

     

    (9,684

    )

     

     

    (9,806

    )

     

     

     

    (37,889

    )

    Series B preferred stock dividend accrued

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (1,798

    )

     

     

     

    (1,798

    )

    Net loss attributable to Bright Health

    Group, Inc. common shareholders

    $

    (204,172

    )

     

    $

    (284,127

    )

     

    $

    (315,755

    )

     

    $

    (691,178

    )

     

     

    $

    (1,495,232

    )

     

     

     

     

     

     

     

     

     

     

     

    Operating Cost Ratio

     

    53.5

    %

     

     

    52.9

    %

     

     

    44.3

    %

     

     

    40.9

    %

     

     

     

    47.2

    %

    (1)The 2022 quarterly Statements of Income (Loss) have been recast to reflect the move of the IFP, MA Legacy and California MA business to discontinued operations as well as to correct the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements and an error identified in the data to account for our risk adjustment factor.

    Bright Health Group, Inc. and Subsidiaries

    Historical Financials

    Recast Income Statement(1)

    (in thousands)

    ($ in thousands)

     

     

     

     

    Three Months Ended

    Consolidated Statements of Income (loss) and operating data:

    March 31,

     

    June 30,

     

    2023

     

     

     

    2023

     

    Revenue:

     

     

     

    Capitated revenue

    $

    49,548

     

     

    $

    49,764

     

    ACO REACH revenue

     

    239,807

     

     

     

    236,994

     

    Service revenue

     

    11,187

     

     

     

    11,222

     

    Investment income

     

    8

     

     

     

    2

     

    Total revenue

     

    300,550

     

     

     

    297,982

     

    Operating costs

     

     

     

    Medical costs

     

    260,120

     

     

     

    245,160

     

    Operating costs

     

    79,518

     

     

     

    70,280

     

    Restructuring charges

     

    301

     

     

     

    1,285

     

    Depreciation and amortization

     

    5,483

     

     

     

    4,671

     

    Total operating costs

     

    345,422

     

     

     

    321,396

     

    Operating Income (Loss)

     

    (44,872

    )

     

     

    (23,414

    )

    Interest expense

     

    7,787

     

     

     

    9,170

     

    Loss from continuing operations before income taxes

     

    (52,659

    )

     

     

    (32,584

    )

    Income tax expense (benefit)

     

    1,259

     

     

     

    (892

    )

    Net loss from continuing operations

     

    (53,918

    )

     

     

    (31,692

    )

    Loss from discontinued operations, net of tax

     

    (115,543

    )

     

     

    (56,935

    )

    Net loss

     

    (169,461

    )

     

     

    (88,627

    )

    Net earnings from continuing operations attributable to noncontrolling interests

     

    (5,550

    )

     

     

    (24,205

    )

    Series A preferred stock dividend accrued

     

    (9,714

    )

     

     

    (9,942

    )

    Series B preferred stock dividend accrued

     

    (2,180

    )

     

     

    (2,231

    )

    Net loss attributable to Bright Health

    Group, Inc. common shareholders

    $

    (186,905

    )

     

    $

    (125,005

    )

     

     

     

     

    Operating Cost Ratio

     

    26.5

    %

     

     

    23.6

    %

    (1)The 2023 quarterly Statement of Income (Loss) have been recast to reflect the move of the IFP, MA Legacy and California MA business to discontinued operations as well as to correct the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements and an error identified in the data to account for our risk adjustment factor.

    Bright Health Group, Inc. and Subsidiaries

    Historical Financials

    Recast Segment Information (1)

    (in thousands)

    (Unaudited)

    Care Delivery

     

     

     

     

    ($ in thousands)

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

    Year Ended

     

    March 31,

     

    June 30,

     

    September 30,

     

    December 31,

     

     

    December 31,

    Statement of income (loss) and operating data:

     

    2022

     

     

     

    2022

     

     

     

    2022

     

     

     

    2022

     

     

     

     

    2022

     

    Revenue:

     

     

     

     

     

     

     

     

     

     

    Capitated revenue

    $

    28,648

     

     

    $

    17,641

     

     

    $

    33,006

     

     

    $

    33,609

     

     

     

    $

    112,904

     

    Service revenue

     

    10,219

     

     

     

    10,691

     

     

     

    10,050

     

     

     

    8,527

     

     

     

     

    39,487

     

    Total unaffiliated revenue

     

    38,867

     

     

     

    28,332

     

     

     

    43,056

     

     

     

    42,136

     

     

     

     

    152,391

     

    Affiliated revenue

     

    368,120

     

     

     

    204,271

     

     

     

    257,707

     

     

     

    209,522

     

     

     

     

    1,039,620

     

    Total segment revenue

     

    406,987

     

     

     

    232,603

     

     

     

    300,763

     

     

     

    251,658

     

     

     

     

    1,192,011

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

    Medical Costs

     

    391,467

     

     

     

    194,531

     

     

     

    264,013

     

     

     

    367,731

     

     

     

     

    1,217,742

     

    Operating Costs

     

    31,195

     

     

     

    32,401

     

     

     

    30,392

     

     

     

    30,797

     

     

     

     

    124,785

     

    Intangible Asset Impairment

     

    —

     

     

     

    —

     

     

     

    42,611

     

     

     

    —

     

     

     

     

    42,611

     

    Depreciation and amortization

     

    6,376

     

     

     

    6,369

     

     

     

    6,374

     

     

     

    3,115

     

     

     

     

    22,234

     

    Total operating expenses

     

    429,038

     

     

     

    233,301

     

     

     

    343,390

     

     

     

    401,643

     

     

     

     

    1,407,372

     

    Operating loss

    $

    (22,051

    )

     

    $

    (698

    )

     

    $

    (42,627

    )

     

    $

    (149,985

    )

     

     

    $

    (215,361

    )

    Care Delivery

     

     

     

     

     

     

     

     

     

     

    ($ in thousands)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

     

     

     

     

    March 31,

     

    June 30,

     

     

     

     

     

     

     

    Statement of income (loss) and operating data:

     

    2023

     

     

    2023

     

     

     

     

     

     

     

    Revenue:

     

     

     

     

     

     

     

     

     

     

    Capitated revenue

    $

    49,548

     

    $

    49,764

     

     

     

     

     

     

     

    Service revenue

     

    10,936

     

     

    10,530

     

     

     

     

     

     

     

    Total unaffiliated revenue

     

    60,484

     

     

    60,294

     

     

     

     

     

     

     

    Affiliated revenue

     

    2,195

     

     

    5,774

     

     

     

     

     

     

     

    Total segment revenue

     

    62,679

     

     

    66,068

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

    Medical Costs

     

    23,722

     

     

    19,720

     

     

     

     

     

     

     

    Operating Costs

     

    29,189

     

     

    32,139

     

     

     

     

     

     

     

    Depreciation and amortization

     

    3,132

     

     

    3,178

     

     

     

     

     

     

     

    Total operating expenses

     

    56,043

     

     

    55,037

     

     

     

     

     

     

     

    Operating income

    $

    6,636

     

    $

    11,031

     

     

     

     

     

     

     

    (1)The segment financials have been recast to reflect the change in our reportable segments and the move of the IFP, MA Legacy and California MA business to discontinued operations as well as to correct the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements.

    Bright Health Group, Inc. and Subsidiaries

    Historical Financials

    Recast Segment Information (1)

    (in thousands)

    (Unaudited)

    Care Solutions

     

     

     

     

    ($ in thousands)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

    Year Ended

     

    March 31,

     

    June 30,

     

    September 30,

     

    December 31,

     

     

    December 31,

    Statement of income (loss) and operating data:

     

    2022

     

     

    2022

     

     

    2022

     

     

     

    2022

     

     

     

     

    2022

    Revenue:

     

     

     

     

     

     

     

     

     

     

    ACO REACH Revenue

     

    182,797

     

     

    137,205

     

     

    145,433

     

     

     

    188,652

     

     

     

     

    654,087

    Service revenue

     

    11

     

     

    41

     

     

    26

     

     

     

    36

     

     

     

     

    114

    Total segment revenue

     

    182,808

     

     

    137,246

     

     

    145,459

     

     

     

    188,688

     

     

     

     

    654,201

    Operating expenses

     

     

     

     

     

     

     

     

     

     

    Medical Costs

     

    176,634

     

     

    134,274

     

     

    146,253

     

     

     

    187,108

     

     

     

     

    644,269

    Operating Costs

     

    2,010

     

     

    2,147

     

     

    2,321

     

     

     

    2,030

     

     

     

     

    8,508

    Total operating expenses

     

    178,644

     

     

    136,421

     

     

    148,574

     

     

     

    189,138

     

     

     

     

    652,777

    Operating income (loss)

    $

    4,164

     

    $

    825

     

    $

    (3,115

    )

     

    $

    (450

    )

     

     

    $

    1,424

    Care Solutions

     

     

     

     

     

     

     

     

     

     

    ($ in thousands)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

     

     

     

     

    March 31,

     

    June 30,

     

     

     

     

     

     

     

    Statement of income (loss) and operating data:

     

    2022

     

     

     

    2023

     

     

     

     

     

     

     

    Revenue:

     

     

     

     

     

     

     

     

     

     

    ACO REACH Revenue

     

    239,807

     

     

     

    236,994

     

     

     

     

     

     

     

    Service revenue

     

    251

     

     

     

    692

     

     

     

     

     

     

     

    Total segment revenue

     

    240,058

     

     

     

    237,686

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

    Medical Costs

     

    238,595

     

     

     

    231,279

     

     

     

     

     

     

     

    Operating Costs

     

    2,972

     

     

     

    3,411

     

     

     

     

     

     

     

    Total operating expenses

     

    241,567

     

     

     

    234,690

     

     

     

     

     

     

     

    Operating income (loss)

    $

    (1,509

    )

     

    $

    2,996

     

     

     

     

     

     

     

    (1)The segment financials have been recast to reflect the change in our reportable segments and the move of the IFP, MA Legacy and California MA business to discontinued operations as well as to correct the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements.

    Non-GAAP Financial Measures

    We use the non-GAAP financial measures Adjusted EBITDA and Adjusted Operating Cost Ratio. We define Adjusted EBITDA as Net Loss excluding loss from discontinued operations, interest expense, income taxes, transaction costs, depreciation and amortization, share-based compensation expense, restructuring costs, contract termination costs, changes in the fair value of contingent consideration, and changes in the fair value of equity securities. We define Adjusted Operating Cost Ratio as Operating Cost Ratio excluding share-based compensation expense. These non-GAAP measures have been presented in this quarterly Earnings Release as supplemental measures of financial performance that are not required by or presented in accordance with GAAP because we believe they assist management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding and including items that we do not believe are indicative of our core operating performance. Management believes these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA and Adjusted Operating Cost Ratio to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

    Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Net Income (Loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for management's discretionary use as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Adjusted Operating Cost Ratio is not a recognized term under GAAP and should not be considered as an alternative to Operating Cost Ratio as a measure of financial performance or any other performance measure derived in accordance with GAAP. The presentation of Adjusted Operating Cost Ratio has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

    ($ in thousands)

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Net loss

    $

    (88,627

    )

     

    $

    (251,330

    )

     

    $

    (258,088

    )

     

    $

    (431,959

    )

    Loss from Discontinued Operations (a)

     

    56,935

     

     

     

    176,568

     

     

     

    172,478

     

     

     

    235,619

     

    EBITDA adjustments from continuing operations

     

     

     

     

     

     

     

    Interest expense

     

    9,170

     

     

     

    337

     

     

     

    16,957

     

     

     

    1,530

     

    Income tax benefit (expense)

     

    (892

    )

     

     

    2,904

     

     

     

    367

     

     

     

    12,885

     

    Transaction costs (b)

     

    8,096

     

     

     

    271

     

     

     

    9,948

     

     

     

    382

     

    Depreciation and amortization

     

    4,671

     

     

     

    8,276

     

     

     

    10,154

     

     

     

    16,336

     

    Share-based compensation expense (c)

     

    15,775

     

     

     

    20,220

     

     

     

    49,095

     

     

     

    53,141

     

    Restructuring costs (d)

     

    1,285

     

     

     

    2,793

     

     

     

    1,586

     

     

     

    9,657

     

    Contract termination costs (e)

     

    —

     

     

     

    500

     

     

     

    —

     

     

     

    500

     

    Change in fair value of contingent consideration (f)

     

    —

     

     

     

    —

     

     

     

    (1,827

    )

     

     

    —

     

    Change in fair value of equity securities

     

    —

     

     

     

    16,184

     

     

     

    —

     

     

     

    57,151

     

    EBITDA adjustments from continuing operations

    $

    38,105

     

     

    $

    51,485

     

     

    $

    86,280

     

     

    $

    151,582

     

    Adjusted EBITDA

    $

    6,413

     

     

    $

    (23,277

    )

     

    $

    670

     

     

    $

    (44,758

    )

    (a)

     

    Beginning in the fourth quarter of 2022, Adjusted EBITDA excludes the impact of discontinued operations. The comparable period in 2022 has been recast to exclude these impacts. Represents losses associated with the Commercial business segment and MA Legacy operations that we exited at the end of 2022 and the California Medicare Advantage business classified as held for sale.

    (b)

     

    Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to financing initiatives. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business.

    (c)

     

    Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards.

    (d)

     

    Restructuring costs represent severance costs as part of a workforce reduction and impairment of certain long-lived assets relating to our decision to exit the Commercial business for the 2023 plan year.

    (e)

     

    Represents amounts paid for early termination of existing vendor contracts and leases. Beginning in the second quarter of 2023, this amount excludes the impact of MA legacy operations that we exited at the end of 2022 as these amounts are now included in the Loss from Discontinued Operations. The adjustment in the comparable period in 2022 has been recast to include these impacts.

    (f)

     

    Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period.

     

     

    The following table provides a reconciliation of Adjusted Operating Cost Ratio for the periods presented:

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2023

     

    2022

     

    2023

     

    2022

    Operating Cost Ratio

    23.6%

     

    52.9%

     

    25.0%

     

    53.3%

    Impact of share-based compensation expense (a)

    (5.3)%

     

    (13.5)%

     

    (8.2)%

     

    (16.1)%

    Adjusted Operating Cost Ratio (b)

    18.3%

     

    39.4%

     

    16.8%

     

    37.2%

    (a)

     

    Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards.

    (b)

     

    The Three Months Ended June 30 and the Six Months Ended June 30 are higher by 3.9% and 5.5%, respectively, due to the impacts of income (loss) driven from unrealized gains and losses on equity securities and realized gains and losses on sales of investments

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230809707967/en/

    Get the next $BHG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHG

    DatePrice TargetRatingAnalyst
    10/11/2022Neutral → Underweight
    JP Morgan
    3/29/2022Overweight → Neutral
    JP Morgan
    3/4/2022$9.00 → $3.00Outperform → Sector Perform
    RBC Capital
    3/3/2022$4.00 → $2.00Underweight
    Morgan Stanley
    3/3/2022$5.00 → $3.50Neutral
    Goldman Sachs
    3/3/2022$5.50 → $4.00Overweight
    Barclays
    3/3/2022$10.00 → $5.00Overweight
    Piper Sandler
    3/2/2022Buy → Underperform
    BofA Securities
    More analyst ratings

    $BHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bright Health Group Inc. (Amendment)

      SC 13G/A - NeueHealth, Inc. (0001671284) (Subject)

      2/14/24 5:04:52 PM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Bright Health Group Inc. (Amendment)

      SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)

      2/14/24 9:37:57 AM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Bright Health Group Inc. (Amendment)

      SC 13D/A - Bright Health Group Inc. (0001671284) (Subject)

      12/22/23 4:34:44 PM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Yang Rick

      4 - Bright Health Group Inc. (0001671284) (Issuer)

      12/21/23 5:05:33 PM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Walker Paul Edward

      4 - Bright Health Group Inc. (0001671284) (Issuer)

      12/21/23 5:04:41 PM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Sandell Scott D

      4 - Bright Health Group Inc. (0001671284) (Issuer)

      12/21/23 5:02:52 PM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Health Group Adopts NeueHealth as Corporate Brand Name

      The Company will advance its value-driven, consumer-centric care model through its owned and affiliated clinics and provider enablement services Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG) today announced that it has adopted NeueHealth as its corporate brand name. This reflects the Company's ongoing focus on its NeueHealth business, which will continue driving long-term sustainable growth of its value-driven, consumer-centric care model, thereby increasing access to high-quality healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid. The Company's common stock will begin trading under the new ticker symbol "NEUE" on the New York Stock

      1/17/24 4:05:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Closes the Sale of its California Medicare Advantage Business to Molina Healthcare

      Completes final repayment on secured credit facility eliminating the Company's secured debt Further focuses on increasing access to value-driven healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid through its continuing business, NeueHealth Reaffirms expectation for Adjusted EBITDA profitability in 2024 Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced that it has successfully completed the sale of its California Medicare Advantage business, Brand New Day and Central Health Plan, to Molina Healthcare, Inc. ("Molina"). The sale closed, effective as of Januar

      1/2/24 4:30:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Strengthens Capital Position with Amendment to its Credit Facility, Impending Close of the Sale of its California Medicare Advantage Business

      Received all required regulatory approvals on the sale of the California Medicare Advantage business; the transaction is expected to close on or about January 1, 2024 Amended Company's secured credit facility to reduce the final repayment resulting in approximately $30 million in savings Meaningfully improves capital position to support continuing business, NeueHealth, a value-driven consumer care delivery and provider enablement business Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced that it entered into an amendment to its credit facility with J.P. Morgan that will reduce the final

      12/29/23 6:45:00 AM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    SEC Filings

    See more
    • Bright Health Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Bright Health Group Inc. (0001671284) (Filer)

      1/24/24 5:09:44 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Bright Health Group Inc. (0001671284) (Filer)

      1/4/24 9:17:32 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Bright Health Group Inc. (0001671284) (Filer)

      1/2/24 4:32:58 PM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Health Group Appoints Jay Matushak as Chief Financial Officer

      Cathy Smith to Step Down to Pursue New Opportunity, Effective May 12, 2023 Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today announced that it has appointed Jay Matushak as the Company's next Chief Financial Officer, effective May 12, 2023. Mr. Matushak will succeed Cathy Smith, who is stepping down to pursue another opportunity. Mr. Matushak, a seasoned finance and operational executive with deep expertise in the healthcare business, joined Bright Health in 2021. He currently serves as Senior Vice President of Finance and is responsible

      5/3/23 5:00:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Announces Retirement of General Counsel Keith Nelsen

      Jeff Craig, lead counsel for the Company's NeueHealth business, named General Counsel and Corporate Secretary Bright Health Group, Inc. ("Bright Health" or "The Company") (NYSE:BHG), the first technology-enabled, Fully Aligned system of care built for healthcare's consumer retail market, today announced that Keith Nelsen will retire as General Counsel and Corporate Secretary. Jeff Craig, lead counsel for the Company's NeueHealth business, will be promoted to the role of General Counsel and Corporate Secretary effective March 18, 2022. Nelsen will stay on as a senior advisor with the Company until June 30, 2022, to ensure a smooth transition. "Keith has been a key leader for many of our mi

      3/15/22 4:35:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Names Leading Healthcare Expert to Board

      Matthew Manders to Join as Independent Director Bright Health Group, Inc. ("Bright Health") (NYSE:BHG), the first technology-enabled, Fully Aligned system of care built for healthcare's consumer retail market, today announced that leading healthcare expert Matt Manders will join the company's Board as an independent director, effective March 1. Manders brings a wealth of diverse healthcare experience, focus on operational excellence, and expertise in consumer-driven healthcare. Most recently, he served as president of Cigna Corporation's Government and Solutions organization, part of a 30-plus-year career with the company. In this role, Manders led and managed Cigna's U.S. Government busi

      3/1/22 8:10:00 AM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bright Health Group downgraded by JP Morgan

      JP Morgan downgraded Bright Health Group from Neutral to Underweight

      10/11/22 12:28:36 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group downgraded by JP Morgan

      JP Morgan downgraded Bright Health Group from Overweight to Neutral

      3/29/22 7:08:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Gr downgraded by RBC Capital with a new price target

      RBC Capital downgraded Bright Health Gr from Outperform to Sector Perform and set a new price target of $3.00 from $9.00 previously

      3/4/22 6:06:15 AM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Financials

    Live finance-specific insights

    See more
    • Bright Health Group Reports Third Quarter 2023 Results

      Q3'23 Revenue from Continuing Business of $269.4 million, up 39% year over year Value-Based Consumers served of 355,000, an increase of 208.7% on a comparable basis from last year on strong growth in Care Delivery Q3'23 Net Loss from Continuing Business of $479.3 million, including a $401.4 million non-cash Goodwill impairment charge; Positive Adjusted EBITDA of $1.2 million in Q3'23 Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability† Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported financial r

      11/7/23 6:45:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023

      Bright Health Group, Inc. ("Bright Health") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Tuesday, November 7, 2023, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via Bright Health's Investor Relations page at investors.brighthe

      10/13/23 8:00:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Reports Second Quarter 2023 Results

      Q2'23 Revenue from Continuing Business of $298.0 million, up 100% year over year Value-Based Consumers served of 371,000, an increase of 214% on a comparable basis from last year on strong growth in Care Delivery Q2'23 Net Loss from Continuing Business of $31.7 million; Positive Adjusted EBITDA of $6.4 million in Q2'23, positive Operating Income in Care Delivery and Care Solutions segments Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability† Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported fi

      8/9/23 6:45:00 AM ET
      $BHG
      Medical Specialities
      Health Care